The effects of bevacizumab on postoperative complications in patients undergoing colorectal and pancreatic cancer resection.
Bevacizumab (Avastin™; rhuMab VEGF), a monoclonal antibody targeting vascular endothelial growth factor (VEGF), has seen increased use in the perioperative treatment of colorectal and pancreatic cancer. Little is known, however, regarding its impact on surgical outcomes in patients undergoing resection. The objective of this review was to examine if the addition of bevacizumab to existing neoadjuvant regimens increases morbidity after cancer resection.
Cheon
E C
EC
Department of Surgery, Mount Sinai Hospital, University of Illinois at Chicago, Chicago, Illinois, USA.
Small
W
W
Strouch
M J
MJ
Krantz
S B
SB
Rademaker
A
A
Mulcahy
M F
MF
Benson
A B
AB
Bentrem
D J
DJ
Talamonti
M S
MS
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000601:surgery; D006801:Humans; D020360:Neoadjuvant Therapy; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000601:surgery; D011183:Postoperative Complications; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab